Pivotal Therapeutics Inc. announced audited consolidated earnings results for the three months ended March 31, 2015. For the period, the company reported a loss of $1.2 million or $0.01 per common share compared with a loss of $1.6 million or $0.02 per common share for the same period last year. Major contributors to the comparative net loss improvement of $421,385 were increases sales of $100,981, reduction in stock based compensation of $508,952, reduced salaries and benefits of $62,960 and a net expense reduction in other items of $81,834 offset by increases in accretion expense of $229,534 and interest on long term debt of $103,808.

Sales were $153,513 as compared to $52,532 for the three months March 31, 2015. The increase in sales is due in part to channel restocking.